GC Biopharma Corp.
Financials
Valuation Metrics
GC Biopharma Corp.'s Market Cap is ₩1.5T. At end of 2025 it was ₩1.9T. Ranked #246 of 2,414 in KR market (top 10%), #188 of 781 on KOSPI (top 24%), #25 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 11%) by Market Cap.
Investment Metrics(as of 2026-10-15)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 1.46T KRW | KR#246/2,414 Sec#25/231 |
| Revenue | 1.96T KRW | KR#261/2,414 Sec#6/231 |
| Net Income | -63.45B KRW | KR—/2,414 Sec—/231 |
| Total Assets | 2.97T KRW | KR#242/2,414 Sec#8/231 |
| Net Assets | 1.39T KRW | KR#228/2,414 Sec#10/231 |
| Employees | 2,355 | KR#124/2,414 Sec#4/231 |
| Value | ||
| P/B | 1.05x | KR#1,558/2,414 Sec#98/231 |
| P/S | 0.74x | KR#1,227/2,414 Sec#64/231 |
| EV/EBITDA | 48.14x | KR#1,348/2,414 Sec#86/231 |
| FCF Yield | 1.85% | KR#1,075/2,414 Sec#71/231 |
| Profitability | ||
| ROE | -4.55% | KR#1,787/2,414 Sec#128/231 |
| ROA | -2.14% | KR#1,765/2,414 Sec#124/231 |
| Op. Margin | 2.41% | KR#1,326/2,414 Sec#95/231 |
| Revenue Growth | 9.73% | KR#912/2,414 Sec#89/231 |
| Earnings Growth | -205.91% | KR#1,240/2,414 Sec#85/231 |
| Financial Health | ||
| Debt Ratio | 113.09% | KR#1,654/2,414 Sec#188/231 |
| Total Debt | 862.25B KRW | KR#226/2,414 Sec#7/231 |
| FCF | 27.10B KRW | KR#439/2,414 Sec#25/231 |
| Cash | 49.37B KRW | KR#743/2,414 Sec#44/231 |
| Current Ratio | 1.35x | KR#1,322/2,414 Sec#139/231 |
| Net Debt/EBITDA | 17.19x | KR#1,346/2,414 Sec#95/231 |
| Dividend | ||
| Div. Yield | 1.20% | KR#1,085/2,414 Sec#62/231 |
| Div. Growth | 0.00% | KR—/2,414 Sec—/231 |
| Performance | ||
| 1Y Return | -4.13% | KR#721/2,414 Sec#42/231 |
| 1M Return | 0.08% | KR#528/2,414 Sec#52/231 |
| From 52W High | -31.88% | KR#494/2,414 Sec#29/231 |
| 1Y MDD | -37.22% | KR#473/2,414 Sec#34/231 |
| Trading | ||
| Volume | 13,689 shares | KR#1,996/2,414 Sec#195/231 |
| Trading Value | 1.71B KRW | KR#623/2,414 Sec#67/231 |
| Foreign Own. | 23.82% | KR#177/2,414 Sec#8/231 |
| Per Share | ||
| EPS | -5,429 KRW | KR—/2,414 Sec—/231 |
| BPS | 119,306 KRW | KR#120/2,414 Sec#6/231 |
Company Info
Established in 1969 and headquartered in Yongin-si, Gyeonggi-do, Green Cross is a professional pharmaceutical manufacturer and seller specializing in blood products and vaccine products. Its main businesses include blood products, general products, and vaccine products. The company strengthened its raw plasma procurement capabilities by acquiring US ABO Holdings in 2025 and is entering the global market with ALYGLO's US FDA approval and 2024 launch. Green Cross supplies products to domestic and international markets through its Ochang factory production facilities, aiming to become a global pharmaceutical company focused on key strategic products.